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Fever: long lasting burden of an acute illness
Daniel Ciampi de Andrade1†, Sylvain Jean2,3†, Pierre Clavelou3†, Radhouane Dallel3†, Didier Bouhassira1*†
Abstract
Background: Chikungunya virus (CHIKV) is responsible for major epidemics worldwide. Autochthonous cases were
recently reported in several European countries. Acute infection is thought to be monophasic. However reports on
chronic pain related to CHIKV infection have been made. In particular, the fact that many of these patients do not
respond well to usual analgesics suggests that the nature of chronic pain may be not only nociceptive but also
neuropathic. Neuropathic pain syndromes require specific treatment and the identification of neuropathic
characteristics (NC) in a pain syndrome is a major step towards pain control.
Methods: We carried out a cross-sectional study at the end of the major two-wave outbreak lasting 17 months in
Réunion Island. We assessed pain in 106 patients seeking general practitioners with confirmed infection with the
CHIK virus, and evaluated its impact on quality of life (QoL).
Results: The mean intensity of pain on the visual-analogical scale (VAS) was 5.8 ± 2.1, and its mean duration was
89 ± 2 days. Fifty-six patients fulfilled the definition of chronic pain. Pain had NC in 18.9% according to the DN4
questionnaire. Conversely, about two thirds (65%) of patients with NC had chronic pain. The average pain intensity
was similar between patients with or without NC (6.0 ± 1.7 vs 6.1 ± 2.0). However, the total score of the Short
Form-McGill Pain Questionnaire (SF-MPQ)(15.5 ± 5.2 vs 11.6 ± 5.2; p < 0.01) and both the affective (18.8 ± 6.2 vs
13.4 ± 6.7; p < 0.01) and sensory subscores (34.3 ± 10.7 vs 25.0 ± 9.9; p < 0.01) were significantly higher in patients
with NC. The mean pain interference in life activities calculated from the Brief Pain Inventory (BPI) was significantly
higher in patients with chronic pain than in patients without it (6.8 ± 1.9 vs 5.9 ± 1.9, p < 0.05). This score was also
significantly higher in patients with NC than in those without such a feature (7.2 ± 1.5 vs 6.1 ± 1.9, p < 0.05).
Conclusions: There exists a specific chronic pain condition associated to CHIKV. Pain with NC seems to be
associated with more aggressive clinical picture, more intense impact in QoL and more challenging
pharmacological treatment.
Background
Chikungunya fever is a viral disease caused by the
arthropod-borne Chikungunya virus, from the Togaviri-
dae family. It is transmitted to humans by the Aedes ssp
mosquitoes. The virus was first isolated in 1953, in
Uganda, during an epidemic in the province of Newala
in Tanganyika (now Tanzania)[1]. Its name derives from
the Makonde language, meaning, “he, who walks bent
up”. The infection gives rise to an unusual clinical find-
ing during its clinical curse: pain, which is virtually
universal and is the major symptom of the disease.
Since the recognition of the first case of CHIKV infec-
tion, both sporadic and major epidemics have been
reported in Africa, India, South-East Asia and Western
Pacific [1,2]. Epidemics of unprecedented magnitude
occurred in 2005-2006 in the islands of the South-West
Indian Ocean. In particular, there was a major outbreak
of CHIKV in Réunion Island, a French overseas départe-
ment (French administrative unit), with 266,000 people
infected, constituting 34% of the island’s total popula-
tion [3].
Interest in this viral infection has grown in recent
years. Competent vectors (i.e. Aedes mosquitoes) are
widely distributed throughout the world; thus many
countries not initially hit by previous epidemics present
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a potential risk of outbreaks [4]. Autochthonous cases
were recently reported in northern Italy [5] and
imported cases in travelers returning from affected areas
have been reported in several European countries and in
the United States of America [6-8]
The clinical course of the acute phase of infection has
been well characterized during previous epidemics in
African countries, the Indian subcontinent and South-
east Asia [1]. It involves an incubation period lasting
between two to six days, followed by the abrupt onset of
fever associated with intense diffuse muscle and joint
pain. Headache, photophobia, nausea, vomiting, diarrhea
and a maculopapular or morbilliform skin rash may
accompany these symptoms. Treatment is mainly symp-
tomatic, with remission observed in most patients some
days after the infection.
Some studies have reported cases in which arthralgia
persists after resolution of the acute infection, thus lead-
ing to chronic pain [9,10]. Despite these initial studies, a
broader characterization of chronic pain related to Chi-
kungunya infection is still needed. In particular, the fact
that many of these patients do not respond well to
usual analgesics suggests that the nature of chronic pain
may be not only nociceptive but also neuropathic. The
neurotropism of CHIK virus, reflected in the neurologi-
cal complications [11], is compatible with this notion.
Given that neuropathic pain syndromes require specific
treatment, including antiepileptics and antidepressants
[12], the potential neuropathic component of this dis-
ease should be a major factor affecting the symptomatic
management of such cases.
We carried out a study at the end of the major two-
wave outbreak lasting 17 months in Réunion Island. The
aims of this study were to assess and characterize pain,
particularly chronic pain in patients attending general
practices who have confirmed serologic infection by the
CHIKV and to evaluate the impact of this pain on qual-
ity of life (QoL).
Methods
This study was approved by our institutions ethics
review board in compliance to the Helsinki declaration.
It was carried out from June to July 2006 in 13 general
practices located throughout Réunion Island. All sub-
jects received written information on the study and gave
written informed consent prior to participation. All
patients spontaneously seeking medical attention were
directly asked whether they were on pain. Patients were
included if they presented with any type of pain and
previous serologic confirmation of CHIKV infection
based on CHIKV IgG and IgM detected by direct ELISA
and ELISA following immunocapture, respectively, as
originally established at the Centre National de Référ-
ence pour les Arbovirus (Pasteur Institute, Lyon, France)
[13]. The enrollment period for the study lasted five
consecutive working days, and each patient was seen
only once. Patients presenting with signs of severe dis-
ease such as meningismus, intense headaches or hemo-
dynamic instability were headed to the nearest hospital
and were not included in the study. We excluded
patients presenting with pain clearly related to any other
etiologies (i.e. rheumatologic, muscular, neurological - i.
e: migraines), or those presenting with diabetes, psychia-
tric illness or a history of drug abuse, including alcohol,
since all these conditions may be associated to specific
painful syndromes and thus might constitute confoun-
ders to our analysis. The assessment included a struc-
tured interview and specific questionnaires to
characterize the painful syndrome and its impact on
QoL [14]. The study was approved by our institution’s
review board and all patients signed a written informed
consent.
The intensity, location and effect of pain on quality of
life were assessed with the Brief Pain Inventory (BPI)
[14]. In this largely used questionnaire, three numerical
rating scales each ranging from 0 (no pain) to 10 (maxi-
mal pain) were used to assess minimal, maximal and
average pain intensity over the previous week. Then
patients were asked to report all sites of pain on a dia-
gram of the body and to specify the location of the
most intense pain. The BPI also includes a series of
numerical rating scales (equally ranging from 0 to 10) to
assess the extent that pain interferes with general activ-
ity, mood, walking, sleep, work, relationship with others
and life enjoyment (from 0: does not interfere, to 10:
complete interference). The short-form McGill Pain
Questionnaire (SF-MPQ) [15] was used to measure the
sensory and affective dimensions of pain. This tool has
been widely used in pain studies. It comprises 15
descriptors (11 sensory; 4 affective) which are rated on
an intensity scale as 0 = none, 1 = mild, 2 = moderate
or 3 = severe. Three pain scores are derived from the
sum of the intensity rank values of the words chosen for
sensory, affective and total descriptors. The DN4-inter-
view questionnaire, includes seven pain descriptors that
must be answered ¨yes¨ or ¨no¨ based on their presence
or absence, respectively, in a given painful body location
[16]. Since this questionnaire is aimed at differentiating
neuropathic pain from other pain syndromes (ie.: noci-
ceptive pain) all its descriptors must be directed to the
same painful phenomenon at a time (ie.: the same body
region). Quite frequently, patients are asked to answer
the questionnaire according to the site of the ¨most
troublesome pain¨. So patients with diffuse pain, but
presenting a body region where pain is more intense
can easily respond to the questionnaire. This method
has been shown to present a high sensibility and specifi-
city in diverse pain trials [12]. However, it is
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recommended that it should not be administered to
patients who have a similar intensity of pain in multiple
locations. The duration of pain was also assessed and
chronic pain was defined as daily pain for more than
three months [17].
In addition, patients were asked to provide details of
current pain treatment (eg.: analgesic drugs prescribed
so far) and their efficacy: low = < 30% pain reduction,
moderate = 30-70% pain reduction and good = > 70%
pain reduction. Pain relief after analgesics was consid-
ered a >30% pain reduction from baseline [12].
Statistical Analysis
Quantitative variables were expressed as means and
standard deviations (SD). Qualitative variables expressed
as proportions and percentages. We used analyses of
variance (ANOVA), with Fisher’s PLSD test, to compare
pain intensity and duration and questionnaire scores
between patients with or without chronic pain and
between patients with or without neuropathic character-
istics. Multiple regression was used to analyze the asso-
ciation between the effect of pain on QoL (i.e. mean
interference score) and clinical characteristics (i.e. age,
pain intensity and duration, DN4 questionnaire score,
SF-McGill sensory and affective scores). The Chi2 test
was used to compare proportions. P < 0.05 was consid-
ered significant in all instances.
Results
Pain characteristics
One hundred and six consecutive painful patients (79
women) were included in this study (47.3 ± 11.9 years).
All reported pain at multiple sites. All patients reported
pain in at least one joint (Table 1). Besides joint pain,
some patients also reported nonarticular pain, especially
on the lower limbs.
The mean intensity of pain measured by the BPI was
5.8 ± 2.1, with minimum and maximum pain intensity
of 3.6 ± 2.1 and 8.3 ± 1.9, respectively.
The mean duration of pain was 89 ± 2 days. Seven-
teen patients (16%) had suffered pain for less than one
month, 33 patients (31%) between one and three
months and 56 (53%) patients suffered chronic pain
(mean: 128 ± 41 days, range: 95-318 days).
Pain had neuropathic characteristics (NC) in 20
patients (18.9%) of patients. Pain with NC was located
mostly in the upper (37%) or lower (48%) limbs and
more rarely in the back (7%) or head/neck (7%).
About half (53%) of patients with NC had chronic
pain. The average pain intensity was similar between
patients with or without NC (6.0 ± 1.7 vs 6.1 ± 2.0).
However, the total score of the SF-MPQ (15.5 ± 5.2 vs
11.6 ± 5.2; p < 0.01) and both the affective (18.8 ± 6.2
vs 13.4 ± 6.7; p < 0.01) and sensory subscores (34.3 ±
10.7 vs 25.0 ± 9.9; p < 0.01) were significantly higher in
patients with NC.
Impact on quality of life
The mean pain interference score calculated from the
BPI was significantly higher in patients with chronic
pain than in patients without (6.8 ± 1.9 vs 5.9 ± 1.9, p <
0.05). This score was also significantly higher in patients
with NC than in those without NC (7.2 ± 1.5 vs 6.1 ±
1.9, p < 0.05).
Multiple regression analysis showed that the interfer-
ence of pain with quality of life was significantly asso-
ciated with average pain intensity, the DN4 score and
SF-MPQ affective score, but not with age or duration of
pain (Table 2). The items altered the most were work-
ing, mood and sleep (Figure 1).
Symptomatic treatment
Eighty-eight (83%) patients had received analgesic treat-
ment for their pain. The most frequently used drugs
included: corticoids (40%), non-steroid anti-inflamma-
tory drugs (NSAID) (22%) and acetaminophen (8%)
(Table 3). Twenty-five (24%) patients reported poor pain
relief, 53 patients (50%) reported moderate pain relief
and 28 (26%) good pain relief with their symptomatic
treatment. The percentage of pain relief was significantly
lower (p < 0.01) in patients with NC (39 ± 24%) than in
patients without NC (56 ± 27%).
Discussion
Our data from a sample of painful patients attending
general practices presenting with pain and serologically
confirmed infection by the CHIKV after the last major
CHIKV outbreak in Réunion Island showed that about
half (51%) of these patients suffered from chronic pain.
Consistent with previous reports, all of our patients pre-
sented with arthralgia. Joint involvement has been
increasingly recognized in CHIKV infections and its rela-
tionship with certain predisposing genetic profiles, such
as HLA B27, has been proposed [18-20]. However, we
identified a subgroup of patients whose most trouble-
some pain was not located in the joints and had neuro-
pathic characteristics (NC) (ie.:, burning pain, cold pain,
electric-shoks like pain, tingling, pins and needles, numb-
ness, itching,). The presence of NC, related with specific
pain mechanisms, was associated with a significantly
poorer quality of life and lower efficacy of treatment.
The association between chronic pain and CHIKV has
been assessed in only a few studies [9,10]. The largest
retrospective study from Réunion Island suggested that
up to 63% of hospitalized patients are affected by
chronic joint pain caused or aggravated by CHIKV
infection [10]. Previous studies focused on chronic
arthralgia and it was suggested that a rheumatoid
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syndrome could be responsible for chronic pain in these
patients. Consistent with this, Brighton and co-workers
[9] found high antibody titers against CHIKV in the
synovial fluid of patients with persistent joint pain and
rigidity (5.6% of patients studied). In our study, although
chronic arthralgia was ubiquitously present, patients also
reported pain in other locations. The mechanisms of
nonarticular chronic pain associated with CHIKV infec-
tion are still poorly understood and remains elusive.
Autopsy studies in other neuroinfectious syndromes,
such as zoster radiculopathy, have shown that even
years after the viral reactivation axonal atrophy and loss
of myelin in peripheral nerves may still be detected.
Also, some major pathological changes, such as dorsal
horn atrophy were present only in those patients pre-
senting chronic pain after the viral reactivation (post-
herpetic neuralgia) [21,22] This argues for the fact that
an active pathological process may take place after the
acute infection, being associated with long term pain
symptomatology. About one out of five of our patients
reported pain with NC, suggesting that other
mechanisms were also involved. Neuropathic pain syn-
dromes are caused by a lesion or dysfunction of the ner-
vous system and their mechanisms are not completely
understood. However, it is well established that neuro-
pathic pain syndromes do not depend directly on
inflammatory processes, but involve specific peripheral
and central changes in nociceptive processes [12,16].
The fact that our patients did not present with obvious
peripheral or central neurological findings may indicate
that NC reflected a dysfunction of the nervous system,
rather than a neurological lesion induced by the
CHIKV. Further clinical and experimental studies will
be needed to identify the putative (peripheral and/or
central) neurological lesion or dysfunction in these
patients.
Nevertheless, this subgroup of patients deserves particu-
lar attention. Indeed, the presence of NC was associated
with a less favorable outcome, in terms of a greater impact
on quality of life and lower efficacy of treatment. In parti-
cular, the poorer outcome of treatment may be explained
Table 1 Description of the patients and percentages of
patients reporting pain at different locations
Clinical and demographic data
Mean age ± SD (range) 47.33 ± 11.9 (19-73)
Sex (women/men) (%) 74.5/25.5
Mean duration of pain (days ± SD) (range) 89.1 ± 55.5 (1-318)
Mean pain intensity ± SD (range) 5.8 ± 2.1 (1-10)
Pain locations %
Head/neck 26
Thorax/abdomen 14
Back 49
Upper Limbs 95
Lower Limbs 98
Location of joint pain
Shoulder 54
Elbow 48
Hand/wrist 77
Hip 9
Knee 72
Ankle/foot 81
Figure 1 Comparison of BPI items related to the impact
("interference”) of pain on quality of life, between patients
with pain with or without neuropathic characteristics.
Abbreviations: relat. others: relationship with others. * p < 0.05; **p
< 0.01; ***p < 0.001
Table 2 Results of the multiple regression analysis showing the association between alteration of mean pain
interference score and mean pain intensity, SF-McGill affective and sensory scores and DN4 questionnaire score
Coefficient Standardized Error Standardized Coefficient t p
age 0.017 0.011 0.107 1.525 0.130
Pain duration 0.001 0.003 0.019 0.271 0.787
Mean pain intensity 0.233 0.069 0.246 3.352 0.0011
SF-McGill sensory -0.51 0.027 -0.154 -1.855 0.066
SF-McGill affective 0.139 0.024 0.495 5.723 <0.0001
DN4 score 0.386 0.088 0.323 4.362 <0.001
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by the fact that neuropathic pain syndromes, which do not
respond to conventional analgesics, respond better to anti-
epileptics and tricyclic antidepressants [12], which were
used in only a minority of our patients.
Whether our findings could be extrapolated to CHIKV
infections in other geographic areas remains uncertain,
since a series of findings suggest that CHIKV infection
during the Réunion outbreak was particularly aggressive.
Thus, more cases with severe neurological complica-
tions, such as meningoencephalitis, requiring intensive-
care units, and the first cases of vertical maternal fetal
transmission were reported during this outbreak
[1-4,23,24]. New viral mutations, not detected during
previous epidemics, were detected during this outbreak
and may thus be related to the more aggressive clinical
progression of the infection [1]. Nevertheless, CHIKV
strains isolated during Réunion Island epidemics show
99.61% homology to strains isolated in India [25]. It is
plausible that such an aggressive infection profile will
affect other regions during future outbreaks [26]. Also,
we found a greater proportion of women with pain
symptoms, which has also been found in large epide-
miological studies [27]. Although a female predisposition
to present pain after CHIKV infection cannot be ruled
out, it could also be related to differences in access to
primary care between men and women. Other studies
are needed to address this question.
Another limitation is that our study was based on the
evaluation of patients in a primary care setting.
Although this allowed a broad assessment of the study
population, more severe cases, treated in secondary and
tertiary centers, may have been missed. We also only
evaluated patients with painful syndromes seeking medi-
cal attention and therefore could not estimate the actual
prevalence of chronic pain in CHIKV infections. Future
prospective studies including long-term follow-up are
warranted to estimate the prevalence of chronic pain
related to CHIKV infections.
Conclusions
This study suggests that chronic pain is a frequent long-
term complication of CHIKV and that the presence of
neuropathic features is associated with a more severe
condition. Thus, although its mechanisms remain to be
determined, improved characterization of pain, including
the identification of neuropathic features with an easy-
to-use clinical tool, could help to significantly improve
treatment outcome.
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